Orexigen Therapeutics, Inc. (OREX) Reports Financial Results for the First Quarter Ended March 31, 2013
5/9/2013 6:29:42 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, May 8, 2013 -- /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter ended March 31, 2013.
For the three months ended March 31, 2013, Orexigen reported a net loss of $19.4 million, or $0.21 per share, as compared to a net loss of $10.4 million, or $0.16 per share, for the first quarter of 2012.
Help employers find you! Check out all the jobs and post your resume.
comments powered by